Myeloperoxidase (MPO) is a heme-containing lysosomal enzyme (EC 1.11.1.7) stored predominantly in azurophilic granules of neutrophils and to a lesser extent in monocytes. Upon degranulation during the oxidative burst, MPO catalyzes the production of hypochlorous acid (HOCl) from hydrogen peroxide (H₂O₂) and chloride ions (Cl⁻), generating bleach-like oxidants that destroy invading pathogens but simultaneously damage host tissues when chronically activated.
MPO is your neutrophil's emergency bleach factory. Imagine a fire station where firefighters respond to a house fire. They arrive with powerful hoses that spray not just water, but industrial-strength bleach solution (HOCl). This bleach annihilates the fire (bacteria, fungi, viruses) instantly—charring wood, melting plastic, destroying everything in its path. The fire is out, crisis averted. But if the firefighters keep spraying bleach day after day in the same neighborhood because of a chronic "smoldering fire," they don't just kill the fire—they corrode the pavement, rust the metal railings, peel paint off houses, and slowly destroy the entire street infrastructure. The neighbors (your own cells) suffer collateral damage: oxidized lipids in cell membranes, carbonylated proteins that don't fold right, DNA breaks. In atherosclerosis, MPO is like a rogue firefighter stationed permanently inside your artery walls, spraying bleach at LDL cholesterol particles, turning them into toxic sludge that macrophages can't resist eating—forming foam cells and plaques. MPO is essential for survival against infection (MPO-deficient patients get severe fungal infections), but chronic activation converts this defense weapon into a tissue demolition crew.
MPO is synthesized in the rough endoplasmic reticulum of myeloid precursors, glycosylated, and packaged into azurophilic (primary) granules during promyelocyte maturation. The enzyme consists of two heavy chains (59 kDa) and two light chains (14 kDa) linked by disulfide bonds, with a heme prosthetic group at the catalytic site.
Activation Cascade:
- Neutrophil priming and activation: PAMPs (LPS, peptidoglycan) or DAMPs (HMGB1, ATP) bind Toll-like receptors (TLR4, TLR2) or cytokine receptors (IL-8, TNF-α) on neutrophil surface
- Intracellular signaling: TLR4 activation → MyD88 → IRAK → NF-κB translocation + PKC activation + PLA2 activation
- Oxidative burst initiation: PKC phosphorylates cytosolic components of NADPH oxidase (NOX2), which assembles at the phagosome membrane
- Superoxide generation: NOX2 catalyzes: NADPH + 2O₂ → NADP⁺ + 2O₂⁻ + H⁺
- H₂O₂ production: Superoxide dismutase converts O₂⁻ to hydrogen peroxide: 2O₂⁻ + 2H⁺ → H₂O₂ + O₂
- MPO release: Neutrophil degranulation releases MPO from azurophilic granules into phagosome or extracellular space
- HOCl synthesis: MPO + H₂O₂ + Cl⁻ → Compound I (ferryl intermediate) → HOCl + H₂O
MPO catalytic cycle:
- Resting state: MPO-Fe³⁺ (ferric heme)
- Compound I formation: MPO-Fe³⁺ + H₂O₂ → MPO-Fe⁴⁺=O·⁺ (two-electron oxidation)
- HOCl production: MPO-Fe⁴⁺=O·⁺ + Cl⁻ + H⁺ → MPO-Fe³⁺ + HOCl
Downstream oxidative products:
- HOCl reacts with proteins → chlorotyrosine, chloramines (stable biomarkers of MPO activity)
- HOCl + taurine → taurine chloramine (longer-lived oxidant)
- MPO + H₂O₂ + NO₂⁻ → nitrogen dioxide (·NO₂), forming 3-nitrotyrosine on proteins
- HOCl oxidizes thiols (GSH) → disulfides, depleting antioxidant reserves
- HOCl + phospholipids → chlorinated lipids, disrupting membranes
graph TD
A[Pathogen/DAMP] --> B[TLR4/Cytokine Receptor]
B --> C["PKC + NF-κB activation"]
C --> D[NOX2 assembly at membrane]
D --> E["NADPH → NADP⁺ + O₂⁻"]
E --> F["SOD: O₂⁻ → H₂O₂"]
F --> G[Degranulation releases MPO]
G --> H["MPO + H₂O₂ + Cl⁻ → HOCl"]
H --> I[HOCl oxidizes proteins/lipids/DNA]
I --> J[Pathogen killing]
I --> K[Host tissue damage]
K --> L[Chlorotyrosine, 3-nitrotyrosine, oxLDL]
L --> M[Chronic inflammation, atherosclerosis, colitis]
Atherosclerotic plaque formation:
MPO oxidizes LDL → oxLDL → scavenger receptors (CD36, SR-A) on macrophages → unregulated uptake → foam cells → fatty streak → plaque. MPO also depletes endothelial nitric oxide (NO + O₂⁻ → peroxynitrite), impairing vasodilation and promoting vasoconstriction.
In the gut:
In IBD and colitis, neutrophil infiltration into lamina propria → MPO release → HOCl damages intestinal epithelium → tight junction disruption (ZO-1, occludin oxidation) → increased gut permeability → bacterial translocation → amplified inflammation.
Cardiovascular disease biomarker:
Plasma MPO >350 ng/mL (ELISA) is an independent predictor of major adverse cardiac events (MACE) within 6 months in patients presenting with chest pain. MPO predicts risk even when troponin and C-reactive protein are normal. MPO in coronary plaques (immunohistochemistry) correlates with plaque rupture risk. The enzyme actively consumes endothelial nitric oxide, contributing to endothelial dysfunction and vasoconstriction—linking the immune system directly to vascular tone.
Inflammatory bowel disease:
Fecal calprotectin (neutrophil protein) and MPO are elevated in active Crohn's disease and ulcerative colitis. MPO activity in colonic biopsies generates HOCl that chlorinates mucosal proteins, creating neoantigens that perpetuate autoimmune responses. This connects to Metamodel 5 (selfish immune system): neutrophils prioritize pathogen defense over host tissue preservation, sacrificing gut barrier integrity when chronically activated.
Periodontitis and oral-systemic axis:
Salivary MPO correlates with periodontal disease severity. Oral neutrophils release MPO in gingival crevicular fluid, oxidizing periodontal ligament collagen and alveolar bone matrix. MPO-modified proteins enter systemic circulation via leaky mouth, contributing to systemic low-grade inflammation and potentially seeding atherosclerotic plaques (Metamodel 3: chronic oral infection → systemic metabolic-immune consequences).
Intervention strategies (cPNI):
- TEMPOL (4-hydroxy-TEMPO, 100 mg/kg in animal models): superoxide dismutase mimetic that scavenges O₂⁻ upstream of MPO, reducing HOCl production. Shown to reduce neutrophil and mast cell infiltration in experimental colitis.
- Vitamin C (1-2 g/day): directly scavenges HOCl and chloramines, regenerating oxidized glutathione.
- Polyphenols (curcumin, quercetin, EGCG): inhibit MPO activity at IC₅₀ ~10-50 μM in vitro, competitive inhibitors at heme site.
- Taurine supplementation (1-3 g/day): preferentially binds HOCl to form taurine chloramine (less reactive than HOCl), acting as a sacrificial antioxidant buffer.
- Omega-3 fatty acids (EPA/DHA): downregulate neutrophil priming and reduce MPO expression via resolvin-mediated signaling (RvD1, RvE1).
- Lifestyle: smoking cessation critical—cigarette smoke induces persistent neutrophil activation and MPO release.
Evolutionary mismatch:
MPO is optimized for acute infections (ancestral threat = intermittent pathogens). Chronic activation in modern environments (processed foods → gut dysbiosis → bacterial translocation; sedentary behavior → metabolic inflammation; chronic psychological stress → cortisol resistance → immune disinhibition) represents mismatch. The enzyme cannot distinguish between a life-threatening sepsis and chronic low-grade endotoxemia.
MPO deficiency (rare genetic mutation):
Autosomal recessive, prevalence ~1:2000-4000. Patients have normal bacterial immunity but increased susceptibility to Candida and Aspergillus infections, proving HOCl is essential specifically for fungal killing (fungal cell walls resist other ROS).
- MPO comprises ~5% of total neutrophil protein mass, making it one of the most abundant enzymes in the body
- Plasma MPO >350 ng/mL predicts cardiovascular events independent of traditional risk factors
- HOCl is 100-1000× more potent as an oxidant than H₂O₂ alone
- MPO generates reactive chlorinating species at pH 5-7 (phagosome and extracellular environments)
- 3-chlorotyrosine and 3-nitrotyrosine are specific biomarkers of MPO activity (measurable in plasma, urine, tissue)
- MPO activity peaks 2-4 hours post-neutrophil activation, with plasma half-life ~4 hours
- In atherosclerotic plaques, MPO co-localizes with oxidized LDL, macrophages, and areas of plaque rupture
- Fecal MPO >2 μg/g stool indicates active intestinal inflammation
- TEMPOL IC₅₀ for MPO inhibition: ~50 μM in vitro
- MPO-deficient individuals have normal lifespan but 10-fold increased fungal infection risk
- neutrophils — primary cellular source of MPO, stored in azurophilic granules and released upon degranulation
- hydrogen peroxide — essential substrate for MPO enzymatic reaction producing HOCl
- hypochlorous acid — principal product of MPO reaction, bleach-like antimicrobial oxidant
- oxidative burst — respiratory burst during which MPO is released and H₂O₂ substrate is generated by NOX2
- reactive oxygen species — MPO generates HOCl, chloramines, nitrogen dioxide as part of broader ROS arsenal
- chloride — required substrate (Cl⁻) for HOCl production; MPO activity depends on physiological chloride concentrations
- inflammation — MPO is biomarker and mediator of acute and chronic inflammatory states
- chronic inflammation — persistent MPO activity drives tissue damage in IBD, atherosclerosis, COPD
- low-grade inflammation — chronic MPO release in metabolic syndrome, obesity, periodontitis
- atherosclerosis — MPO oxidizes LDL creating atherogenic particles, depletes endothelial NO, promotes plaque instability
- LDL — oxidized by MPO-derived HOCl, creating oxLDL recognized by scavenger receptors
- foam cells — macrophages that engulf MPO-oxidized LDL accumulate in arterial intima forming fatty streaks
- cardiovascular disease — plasma MPO independent risk factor for myocardial infarction and stroke
- endothelial dysfunction — MPO consumes nitric oxide via peroxynitrite formation, impairing vasodilation
- IBD — elevated fecal and mucosal MPO in Crohn's disease and ulcerative colitis
- colitis — MPO drives intestinal epithelial damage in experimental and human inflammatory bowel disease
- periodontitis — salivary and gingival crevicular MPO correlates with periodontal destruction
- gut permeability — MPO-generated HOCl oxidizes tight junction proteins (ZO-1, occludin) increasing leaky gut
- mast cells — infiltrate alongside neutrophils in inflammation; both cell types contribute to oxidative tissue damage
- tissue damage — collateral damage from MPO activity in chronic inflammatory diseases
- TEMPOL — superoxide dismutase mimetic that reduces upstream O₂⁻, limiting substrate for MPO
- vitamin C — directly scavenges HOCl and chloramines, regenerates glutathione
- curcumin — polyphenol MPO inhibitor, competitive at heme catalytic site
- quercetin — flavonoid with MPO inhibitory activity and broader antioxidant effects
- EPA/DHA — omega-3s reduce neutrophil priming and MPO expression via resolvin signaling
- resolvins — specialized pro-resolving mediators (RvD1, RvE1) that downregulate neutrophil activation and MPO release
- calprotectin — fecal biomarker of neutrophil activity often measured alongside MPO in IBD
- oxidative stress — MPO major contributor in inflammatory conditions, generating chlorinated and nitrated protein adducts
- nitric oxide — depleted by MPO-generated peroxynitrite (NO + O₂⁻), impairing vascular function
- glutathione — antioxidant depleted by HOCl oxidation; GSH/GSSG ratio marker of oxidative burden
- NF-κB — transcription factor activated upstream of neutrophil priming, regulating MPO gene expression
- TLR4 — pattern recognition receptor triggering neutrophil activation and MPO release in response to LPS
- monocytes — secondary source of MPO (lower levels than neutrophils), contribute to chronic inflammation
- macrophages — differentiated monocytes that engulf MPO-oxidized LDL in atherosclerotic plaques
- Module 5 — Organs I: gut barrier function, intestinal inflammation, MPO in colitis models
- Module 6 — Wound healing: neutrophil infiltration, oxidative phase of inflammation, tissue damage vs pathogen killing